26.09.2019 • NewsElaine BurridgeEvotecTakeda

Evotec and Takeda in Drug Discovery Pact

Evotec and Takeda in Drug Discovery Pact (c) Takeda
Evotec and Takeda in Drug Discovery Pact (c) Takeda

German drug discovery and development company Evotec has entered into a strategic, multi-year collaboration with Japan’s Takeda Pharmaceutical that could be worth in excess of $850 million.

The partners aim to establish at least five drug discovery programs with the goal of Evotec delivering clinical candidates for Takeda to pursue into clinical development. The collaboration will see the companies combine their expertise to discover new treatments in Takeda’s four core therapeutic areas: oncology, gastroenterology, neuroscience and rare diseases.

Under the terms of the deal, the Osaka-headquartered drugmaker will pay Evotec an undisclosed, one-time, upfront fee. In addition, Evotec is eligible to receive pre-clinical, clinical and commercial milestones that could total more than $170 million per program as well as tiered royalties on future sales.

Takeda, which merged with Shire in January, and Evotec are also working together on a treatment for neurodegenerative diseases that cause dementia.

Last year Evotec signed collaborations with Sanofi and Celgene in the areas of infectious diseases and oncology respectively. The Hamburg-based company is also working with Bayer on a treatment for chronic kidney diseases.

More recently, in July this year, Evotec closed its $90 million purchase of US biologics company Just Biotherapeutics.

 

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.